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S242 Poster Session Ireducing HLH related immunopathology, this strategy leads to pro-
found iatrogenic marrow and immune suppression, thus greatly in-
creasing the risk of opportunistic infection. With the explosion of
cinically available immunosuppressive agents, there is a critical
need to define which sorts of immune suppression offer the most ef-
fective yet focused treatment for HLH.
In this study, we utilize our animal model of HLH as a preclinical
screen to test the effectiveness of targeted immune suppression using
agents that interfere with interleukin-2 production or signal trans-
duction in T cells. LCMV-infected prf-/- mice experience exagger-
ated symptomaticity, massive elevations in serum IFNg, and
consumptive anemia before becoming moribund. When these mice
are treated with the mTOR inhibitor rapamycin, either alone or in
combination with inhibitors of T cell costimulation (CTLA4-Ig or
anti-CD2), they show improvements in disease severity, survival,
and hemoglobin levels similar to the benefit seen in animals treated
with etoposide monotherapy. We will present data showing the ef-
fects of these agents on the activation of dendritic cells, T cells,
and macrophages in the context of our animal model.226
OUTCOMES AFTER ADDITION OF RABBIT-ATG TO THE STANDARD
BU + CY PREPARATIVE REGIMEN FOR ALLOGENEIC MATCHED SIBLING
DONOR (MSD) HEMATOPOIETIC STEM CELL TRANSPLANTATION
(HSCT) FOR HEMOGLOBINOPATHIES IN CHILDREN
Soni, S.1, Skeens, M.1, Gross, T.G.1, Bajwa, R.P.1, Baker, S.K.2,
Termuhlen, A.1 1Nationwide Children’s Hospital, Columbus, OH;
2Fred Hutchinson Cancer Research, Seattle, WA
Introduction: Allogeneic HSCT for hemoglobinopathies following
myeloablative conditioning in MSD setting results in excellent out-
comes in children (85-95% 5 year EFS). Though outcomes are en-
couraging, there is still a 7%-10% incidence of graft rejection and
15-20% incidence of GVHD.We proposed the hypotheses, that ad-
ministration of 10 mg/kg dose of rabbit-ATG (Thymoglobulin,
Genzyme, Cambridge, USA) during the peri-transplant period for
MSDHSCT,will lead to partial in-vivoT-cell depletion; eliminating
the risk of rejection andGVHDwhile not increasing the risk of infec-
tions.
Methods: Patients with sickle cell disease (SCD) with sequelae and
transfusion dependent b-thalassemia, underwentMSDHSCT on an
IRB approved study starting Jan, 2003. All patients received iv Busul-
fan (16 mg/kg over 4 days; targeted AUC of 900-1350 mM/mt, based
on 1st dose PK); Cyclophosphamide (50 mg/kg 4 days) and r-ATG
(2.5 mg/kg/day from days -6 to -3). Cyclosporine and standard short
course Methotrexate on days +1, +3 and +6 was given for GVHD
prophylaxis.
Results: 11 patients (9 SCD and 2 b-Thalassemia; 6 females and 5
males) have received the preparative regimen. Median age of patients’
was 4 years (range,18 months-18 years). The r-ATG infusions were
well tolerated with no missed doses. All patients received sibling BM
grafts with the median cell dose of 3.5  108 TNC/kg (range, 1.8-
10.1  108 TNC/kg). All patients developed grade II-III mucositis.
One patient developedmild VOD and one patient had seizures associ-
ated with reversible posterior leuco-encephalopathy syndrome. All pa-
tients engrafted (ANC.0.5 109/L) bymedianof day +15 (range, day
+10 to +23). 2 patients developedCMVreactivations that responded to
treatment. No other viral reactivations or fungal infections were de-
tected. Serial chimerism analysis post-HSCT shows stable donor en-
graftment in all patients. There was no TRM and none of the
patients developed acute GVHD. One patient developed limited
chronic GVHD of the skin. EFS is 100% after a median follow up of
404 days (range, 61-2409 days) with complete resolution of underlying
disease. End organ function is stable and immune reconstitution is
complete in all the patients evaluable.1 year post-HSCT.
Conclusions:Addition of 10 mg/kg dose of rabbit-ATG to the stan-
dard Bu + CYmyeloablative regimen has minimized the incidence of
rejection, acute and chronic GVHD without increasing toxicity or
incidence of infections for MSD HSCT for hemoglobinopathies.227
OUTCOME OF UNRELATED DONOR BLOOD AND MARROW TRANSPLAN-
TATION (BMT) FOR CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKE-
MIA (ALL) IN THIRD REMISSION
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Woolfrey, A.2, MacMillan, M.6, Eapen, M.3, Davies, S.7,
Frangoul, H.8 1Doernbecher Children’s Hospital, Oregon Health & Sci-
ence University, Portland, OR; 2Fred Hutchinson Cancer Research Center,
Seattle, WA; 3Medical College of Wisconsin, Center for International
Blood and Marrow Transplant Research, Milwaukee, WI; 4Medical Col-
lege of Wisconsin, Milwaukee, WI; 5 Instituto de Oncologia Pediatrica,
Sao Paulo, SP, Brazil; 6University of Minnesota Medical Center, Minne-
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Although BMT plays an important role in the therapy of ALL, the
outcome of children transplanted in third remission (CR3) is poorly
defined. We reviewed 155 children, median age 11 years (range, 1-
18), who received an unrelated donor BMT for ALL in CR3 from
1990 to 2005. Median time from diagnosis to first relapse was 35
months, and median time from first to second relapse was 26 months
(range, 4-116). Stem cell sources were bone marrow (n5 115), pe-
ripheral blood stem cells, PBSC (n5 11) or cord blood (n5 29).
BM and PBSC donor-recipient pairs (n5 126) were matched at
HLA-A, B, C and DRB1 (n5 40, 32%), or mismatched at either
one locus (n5 36, 28%) or$ 2 loci (n5 50, 40%). Cord blood do-
nor-recipient pairs (n5 29) were matched at HLA-A, B, DRB1
(n5 1) or mismatched at either one locus (n5 6) or 2 loci
(n5 22). 92% of patients received total-body irradiation (TBI) and
42% received TBI dose .1300 cGy. Graft vs. host disease
(GVHD) prophylaxis was cyclosporine or tacrolimus plus another
agent in 63% of patients. 31% of patients received T-cell depleted
BM grafts and 52% received ATG as part of transplant conditioning
regimen. The cumulative incidence of neutrophil recovery was 95%
(95% CI, 95- 98%). The day-100 cumulative incidence of grade 2-4
acute GVHD was 58% (50-66%) and chronic GVHD at 3-years,
28% (95% CI 21-35%). The risk of chronic GVHD higher in
PBSC recipients (RR 2.85, 95% CI1.18-6.92, p5 0.01). The inci-
dence of non-relapse mortality (NRM) was 19% (95% CI 14-
26%) at 100 days, 41% (95% CI 33-49%) at 1-year and 45% (95%
CI 37-53%) at 5-years. Causes of NRM included graft failure
(2%), GVHD (5%), infection (12%), organ toxicity (21%), second-
ary malignancies (3%) and other causes (6%). 47 patients are alive at
last follow-up, with median follow-up of 6 years. In multivariate
analysis, the interval between first and second relapse was associated
with relapse after BMT. Relapse risks were higher in patients for
whom this interval was #26 months (RR 2.50, 95% CI 1.28-4.76,
p5 0.01). No risk factors were identified for non-relapse mortality.
The 5-year cumulative incidence of relapse was 17% (95% CI 9-
26%) and 34% (95% CI 24-45%) in patients with a second relapse
.26 months and #26 months from their first relapse, respectively.
Corresponding 5-year leukemia-free survival rates were 33% (95%
CI 23-44%) and 26% (95% CI 16-36%). Unrelated donor BMT re-
sults in acceptable disease free-survival in children with ALL in CR3,
especially those experiencing a late second relapse.228
REDUCED INTENSITY CONDITIONING (RIC) WITH FLU-BU-ATG AND AL-
LOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)
FROM HLA IDENTICAL DONORS: RELAPSE-FREE SURVIVAL (RFS) OF
42% IN PEDIATRIC PATIENTS WITH HIGH-RISK HEMATOLOGIC MALIG-
NANCIES
Duerst, R.E., Jacobsohn,D.A., Schneiderman, J., Chaudhury, S., Tse,W.,
Kletzel, M. Children’s Memorial Hospital and Northwestern University,
Feinberg School of Medicine, Chicago, IL
RIC regimens prior to allogeneic HSCT diminish potential com-
plications compared with myeloablative therapy. We report the ex-
perience of 31 RIC HSCT for children/adolescents with
hematologic malignancies at high-risk for relapse or complications
of full-intensity conditioning due to disease state, prior myeloabla-
tive HSCT and/or co-morbid conditions. The RIC regimen was
comprised of fludarabine, 180 mg/m2 over 6 days, 2 days of IV bu-
sulfan; and 4 days of ATG (equine or rabbit). Diagnoses included:
ALL (14, $CR3 in 7), AML (5), treatment-related myelodysplastic
Poster Session I S243syndrome/secondary AML (5), Non-Hodgkin’s Lymphoma (4), or
CML (3). There were 22 males, 9 females, ages 2 – 17 yrs, median
11. Ten patients (pts) had previously undergone myeloablative ther-
apy and HSCT, 8 pts had comorbid conditions increasing their risk
for treatment failure. Stem cell sources included 16 unrelated donors
(URD), 13 matched sibs and 2 mis-matched relatives. 29 of 31 HSC
donations were frommobilized peripheral blood and 2 weremarrow.
Graft-versus-host disease (GVHD) prophylaxis was cyclosporine A
(CsA) alone in 9 pts and CsA and mycophenolate in 22 pts. Median
time to an ANC .500/mcl was 18 days and unsupported platelet
count .20,000/mcl was (28 pts) 17 days, 7 pts required no platelet
support. One pt failed to engraft and 3 had secondary graft loss. 6
pts developed Grade III-IV acute GVHD, 14 of the 24 pts surviving
more than 100 days developed chronic GVHD (8 limited, 6 exten-
sive). 16 pts survive, 10 without disease relapse or progression.
100-day mortality (7 of 31, 23%) was from infection (3), GVHD
(3) and relapse (1). 8 of 19 pts with matched donors relapsed, 2
died of infections complicatingGVHDwhereas 3 of 12 pts with mis-
matched donors relapsed, 7 died of complications: infection, GVHD
or graft failure.
RFS for patients HLA-matched at the allele (8 of 8) level was 42%
vs 18% (p5 0.04) with$ 1 mismatch while Overall Survival was
64% vs 24% (p5 0.02). Our results suggest RIC allogeneic HSCT
should be considered for pediatric pts with hematologic malignan-
cies, especially if a well-matched (related or unrelated) donor can
be identified. Our current studies are focused on reducing the toxic-
ity for recipients of mismatched grafts.
Patient Characteristics (n5 31)
Age—yrs, (median, std dev) 11 1/- 4
M – F 22 – 9
Prior Autologous HSCT 6
Prior Allogeneic HSCT 4
Matched Sib HSC 13URD or mm Relative HSC 18
HSC Dose–CD341 cells/kg, x10e6 (median,
std dev)8.8 1/- 5.7229
OUTCOME OF HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)
IN CHILDREN WITH CONGENITAL HEART DISEASE (CHD)
Guinan, E.C.1,2, Hewett, E.K.2, Domaney, N.M.2, Margossian, R.3
1Children’s Hospital, Boston, MA; 2Dana-Farber Cancer Institute, Bos-
ton, MA; 3Children’s Hospital, Boston, MA
CHD is the most common birth defect in the US. Improved sup-
portive care has resulted in more pediatric and adult survivors who
may develop indications for HSCT. We hypothesized there would
be overrepresentation of CHD in children undergoing HSCT, as
several inherited immune and bone marrow (BM) failure disorders
are associated with an increased CHD prevalence. As HSCT out-
comes of patients (pts) with CHD are not well known, we conducted
a retrospective chart review of 1185 sequential HSCT on 1031 pts
performed at Children’s Hospital Boston from 1989-2007. We
found 10 pts with major cardiac structural defects requiring surgical
catheterization or intervention for repair or palliation. Cardiac char-
acteristics are outlined in the table. 8 pts underwent allogeneic
HSCT for ALL (n5 4), AML (n5 1), CML (n5 1), Diamond-
Blackfan anemia (n5 1), and DiGeorge syndrome (n5 1) using
BM from matched sibling (n5 4) or unrelated donors (n5 3). 1 pt
received fresh T cells from a haploidentical donor. 2 pts underwent
autologous HSCT using BM for ALL (n5 1) and AML (n5 1).
Conditioning was cyclophosphamide (CY) and TBI +/- other che-
motherapy (n5 7) or CY +/- other chemotherapy (n5 2). The hap-
loidentical HSCT was performed without conditioning. GVHD
prophylaxis was cyclosporine and methotrexate, plus corticosteroids
for some unrelated BM recipients. Median time to absolute neutro-
phil count of 500/uL was 25 days (D, range 17-50). 2/8 allogeneic
HSCT recipients developed acute GVHD (1 Grade 2, 1 Grade 3).
1 received systemic corticosteroids. 50% of pts developed febrile
neutropenia. 2 had documented bacteremia, but no endocarditis or
life-threatening infectious toxicity was seen. Combined rates of
grade 3, 4, and 5 cardiac, pulmonary, and renal toxicities (NIH
CTC v. 3) through D + 100 were 10%, 10%, and 0%, respectively.
No pts died in the first 100 D post-HSCT. Pt follow-up ranged0.44-9.25 yrs (median 3.9yrs). 5 pts died at a median of 690D (range
159-780) of relapse (n5 4) and pulmonary hemorrhage (n5 1). 5 pts
underwent post-HSCT cardiac repair. 4 procedures were completed
uneventfully; 1 pt died of sepsis and pulmonary hemorrhage. Overall
CHD rates were 2-5  greater in our pts than US rates. We found
promising acute and long-term HSCT outcomes for children with
CHD, who readily tolerated HSCT associated volume challenges,
febrile neutropenia, and regimen-related toxicity, and suggest that
children with CHD should not be excluded from HSCT solely
due to their cardiac anomalies.
Cardiac Status on Admission
AgePatient
T
pat
rans-
lantCardiac
DiagnosisPrior
SurgeryPrior
AnthracyclineChronic
Cardiac
Rx1 2.5 Complex single
right ventricle
Bidirectional
Glenn shunt
No Enalapril,
aspirin2 5.3 Coarctation,
patent ductus
arteriosus
None Doxorubicin
60 mg/m2 1
dexrazoxane
None3 8.9 Truncus
Arteriosus Type
1A, ventricular
septal defect
Truncus repair No Enalapril4 13.9 Atrial septal
defect
None Daunorubicin
135 mg/m2
None5 0.3 Tetralogy of
Fallot
Tetralogy of
Fallot repair
No Digoxin6 8 Pulmonary
stenosis
Pulmonary
balloon
valvuloplasty
Doxorubicin
60 mg/m2
None7 10.6 Atrioventricular
canal defect
Atrioventricular
canal defect
repair
Doxorubicin* None8 18.5 Primum atrial
septal defect, cleft
mitral valve
None Daunorubicin
135 mg/m2
None9 1.5 Bicommissural
aortic valve,
coarctation,
mitral stenosis,
ventricular septal
defect
None Daunorubicin
128 mg/m2;
Idarubicin
30.6 mg/m2
None10 6.3 D-loop
transposition of
the great arteries,
ventricular septal
defect, pulmonary
stenosis
Blalock-Taussig
shunt, Rastelli
procedure,
conduit
revision,
pulmonary
valve
replacement
Doxorubicin
60 mg/m2 1
dexrazoxane
Aspirin*Initial care at outside institution, cannot confirm dose.230
RISK ADAPTED ALLOGENEIC STEM CELL TRANSPLANTATION (ALLOSCT)
FOR ACQUIRED SEVERE APLASTIC ANEMIA (SAA) IN PEDIATRIC RECIPI-
ENTS: IMPROVED OUTCOMES WITH UNRELATED DONORS
Mc Guinn, C.1, Geyer, M.B.1, Jacobson, J.S.2, Garvin, J.H.1,
Baldinger, L.1, van de Ven, C.1, Bhatia, M.1, Satwani, P.1,
Bradley, M.B.1, George, D.1, Schwartz, J.3, Morris, E.1, Hawks, R.1,
Foley, S.1, Baxter-Lowe, L.A.4, Cairo, M.S.1,3,5 1Morgan Stanley Child-
ren’s Hospital of New York Presbyterian, ColumbiaUniversity, NY; 2Her-
bert Irving Comprehensive Cancer Center, and Joseph L. Mailman School
of Public Health, Columbia University, New York, NY; 3Columbia Uni-
versity, New York, NY; 4University of California, San Francisco, CA;
5Columbia University, New York, NY
Background: AlloSCT from matched sibling donors (MSD) has re-
sulted in the highest survival rates in children and adolescents with
